[A20-60] Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis
Last updated 04.10.2023
Project no.:
A20-60
Commission:
Commission awarded on 16.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Report
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Note:
The current version 2.1 of of the report plan replaces version 2.0 published on 2021-08-20.